← Database
M&A

VITAL DIAGNOSTICS

Acquired by

ELITECH GROUP

UNITED STATES Life Sciences REV [1m USD - 100m USD] 01/2013

Target

VITAL DIAGNOSTICS

Acquirer

ELITECH GROUP

Context

Instead of a simple territorial expansion, this cross-border maneuver acts as a catalyst for ELITech Group’s "300 Million Euro" roadmap, fundamentally rebalancing its geographic revenue split. By capturing Vital Diagnostics, the group secures a turnkey infrastructure for the US physician office laboratory market while gaining an immediate foothold in the Australian and New Zealand clinical sectors. The strategic rationale centers on the industrial synergy between the target’s benchtop analyzer expertise and the group's established chemical reagent pipeline.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 12.8x since the beginning of 2026, 1.8% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Vital Diagnostics operates as a premier technology organization dedicated to the engineering and distribution of clinical chemistry analyzers and specialized reagents. The entity’s business model is centered on a proprietary framework of benchtop diagnostic systems specifically designed for the physician office laboratory (POL), small-to-medium-sized hospitals, and specialized clinics. Its value proposition is anchored in technical operational depth, providing integrated hardware and chemical assay solutions that facilitate decentralized medical testing. Strategically, the firm focuses on the "near-patient" testing niche, ensuring that diagnostic results are both rapid and accurate within primary care settings. By maintaining a specialized focus on clinical chemistry and hematology, the organization ensures a mission-critical role in the structural efficiency of laboratory workflows across North America and Australasia. The entity prioritizes manufacturing quality and technical support to facilitate the structural advancement of community-based healthcare diagnostics.

Ent. Value

LOGIN

Equity Value

LOGIN

Multiples Analysis

EV / Revenue

LOGIN

EV / EBITDA

LOGIN

EV / EBIT

LOGIN

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2012
LOGIN
LOGIN
LOGIN
2011
LOGIN
LOGIN
LOGIN

Other operations with VITAL DIAGNOSTICS

mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.